
1. antimicrob agents chemother. 2015 sep;59(9):5511-9. doi: 10.1128/aac.00602-15.
epub 2015 jun 29.

resistance antimicrobial agent fosmidomycin fr900098 prodrug
through mutations deoxyxylulose phosphate reductoisomerase gene (dxr).

armstrong cm(1), meyers dj(2), imlay ls(3), freel meyers c(2), odom ar(4).

author information: 
(1)department pediatrics, washington university school medicine, st. louis,
missouri, usa.
(2)department pharmacology molecular sciences, johns hopkins school of
medicine, baltimore, maryland, usa.
(3)department molecular microbiology, washington university st. louis, st. 
louis, missouri, usa.
(4)department pediatrics, washington university school medicine, st. louis,
missouri, usa department molecular microbiology, washington university st. 
louis, st. louis, missouri, usa odom_a@kids.wustl.edu.

there pressing need new antimicrobial therapies combat globally
important drug-resistant human pathogens, including plasmodium falciparum
malarial parasites, mycobacterium tuberculosis, gram-negative bacteria,
including escherichia coli. organisms possess essential
methylerythritol phosphate (mep) pathway isoprenoid biosynthesis, not
found humans. first dedicated enzyme mep pathway,
1-deoxy-d-xylulose 5-phosphate reductoisomerase (dxr), inhibited the
phosphonic acid antibiotic fosmidomycin analogs, including n-acetyl
analog fr900098 phosphoryl analog fosfoxacin. order identify
mutations dxr confer resistance drugs, library e. coli dxr 
mutants screened lethal fosmidomycin doses. resistant allele
(with s222t mutation) alters fosmidomycin-binding site dxr. the
expression resistant allele increases bacterial resistance to
fosmidomycin fosmidomycin analogs 10-fold. observations
confirm primary cellular target fosmidomycin dxr. furthermore,
cell lines expressing dxr-s222t powerful tool confirm mechanisms
of action future fosmidomycin analogs.

copyright Â© 2015, american society microbiology. rights reserved.

doi: 10.1128/aac.00602-15 
pmcid: pmc4538460
pmid: 26124156  [indexed medline]

